

April 25, 2022

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi - 74000

GlaxoSmithKline Pakistan Limited 35-Dockyard Road, West Wharf, Karachi - 74000, Pakistan

UAN+92 21 111 475 725 Fax +92 21 3231 4898 www.pk.gsk.com

Subject:

Financial Results for the Quarter ended March 31, 2022

Dear Sir,

We have to inform you that the Board of Directors of our company in their meeting held on Monday, April 25, 2022 at 2:00 p.m. in GSK Pakistan Limited, Sykes Building, 35 – Dockyard Road, West Wharf, Karachi, recommended the following:

(i) CASH DIVIDEND

NIL.

The financial results of the Company are as follows:

	March 31, 2022	March 31, 2021
	Rs '000	
Revenue from contracts with customers Cost of sales	8,625,964 (6,388,456)	7,693,509 (5,813,566)
Gross profit Selling, marketing and distribution expenses	2,237,508 (696,750)	1,879,943 (698,092)
Administrative expenses	(391,983)	(372,729)
Other operating expenses Other income	(120,561) 474,037	(98,266)
Operating profit	1,502,251	1,132,048
Financial charges	(115,789)	(1,982)
Profit before taxation Taxation	1,386,462 (461,421)	1,130,066 (404,519)
Profit after taxation	925,041	725,547
Earnings per share	Rs. 2.90	Rs. 2.28





The financial statements for the quarter ended March 31, 2022 of the Company will be transmitted through PUCARS in stipulated time.

Yours Sincerely,

Mehar-e-Daraksha Ameer Company Secretary

CC:

Head of Operation, Central Depository Company of Pakistan Limited, 99-B, Block – B, S.M.C.H.S., Main Shahra-e-Faisal, Karachi – 74000

Director/HOD, Surveillance, Supervision and Enforcement Department Securities and Exchange Commission of Pakistan NIC Building, 63 Jinnah Avenue, Blue Area, Islamabad

